Effectiveness of ointment that kills antibiotic-resistant bacteria shown
Study shows topical drug promotes wound healing in a variety of burn
injuries

Date:
December 1, 2021
Source:
University of Cincinnati
Summary:
New research shows that use of a topical drug, called
AB569, a combination of acidified nitrite and EDTA
(or ethylenediaminetetraacetic acid) promotes killing of
antibiotic-resistant bacteria while enhancing the healing of wounds
in a variety of burn injuries.



FULL STORY ========================================================================== Research from the University of Cincinnati College of Medicine shows
that use of a topical drug, called AB569, a combination of acidified
nitrite and EDTA (or ethylenediaminetetraacetic acid) promotes killing
of antibiotic-resistant bacteria while enhancing the healing of wounds
in a variety of burn injuries.

The study was published in the journal Infection and Immunity.


========================================================================== AB569 was patented in the United States in 2018 by Daniel Hassett,
PhD, professor in the Department of Molecular Genetics, Biochemistry
and Microbiology at the UC College of Medicine. Hassett's research has
found that AB569 kills virtually all pathogenic bacteria tested with
no observed acquired resistance. These, including multidrug resistant Pseudomonas aeruginosa (MDR- PA), are some of the most serious pathogens according to the Centers for Disease Control and Prevention exhibiting multidrug resistance and enhanced virulence properties.

"Multidrug resistant bacteria, often called 'superbugs,' are an
ever-burgeoning global health problem," says Hassett. "As a result,
there is a critical need to develop novel and effective antimicrobials
for the prevention, treatment and eradication and healing of such wounds
that are complicated by the most formidable pathogen of burn patients,
known as MDR-PA. Injury severity is predominantly due to potentially
lethal sepsis caused by MDR-PA." Hassett, who is the co-corresponding
author on this study with Latha Satish, PhD, director of clinical lab operations at Cincinnati Children's Hospital Medical Center, says the
research shows AB569 acts synergistically to kill all human burn wound
strains of the pathogen in vitro.

"AB569 not only kills the bug, it also enhances the wound-healing
process," says Hassett. "At the same time, AB569 topical application significantly increases the anti-inflammatory mediators...that allow
improved epidermal restoration and the healing process to occur more
rapidly and efficiently." AB569 was initially seen as a potential
treatment for many antibiotic-resistant organisms that cause pulmonary infections in patients with cystic fibrosis and chronic obstructive
pulmonary disease (COPD) and many other opportunistic infections. In
addition to tackling COPD and cystic fibrosis, AB569 may also be effective
in addressing infections related to severe burns, urinary tract disorders, endocarditis and diabetes, said Hassett.

"This study provides solid foundational evidence that AB569 can be used topically to treat highly problematic dermal [injuries] including wound,
burn, blast and likely diabetic infections in civilian and military
populations and help relieve the economical burden that MDR organisms
have on the global health care system," says Hassett.

Disclosures: Hassett is a stockholder and principal scientist at
Arch Biopartners. AB569 is currently in a Phase 1 human trial at the
Cincinnati VA Medical Center in healthy volunteers testing its safety
and pharmacokinetic profile. AB569 has been licensed by the University
of Cincinnati exclusively to Arch Biopartners, a Toronto-based publicly
traded biotechnology company.

========================================================================== Story Source: Materials provided by University_of_Cincinnati. Original
written by Bill Bangert. Note: Content may be edited for style and length.


========================================================================== Journal Reference:
1. Amanda Barry, Warunya Panmanee, Daniel J. Hassett, Latha
Satish. AB569, a
Novel, Topical Bactericidal Gel Formulation, Kills Pseudomonas
aeruginosa and Promotes Wound Healing in a Murine Model of Burn
Wound Infection.

Infection and Immunity, 2021; 89 (11) DOI: 10.1128/IAI.00336-21 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/12/211201145306.htm

--- up 2 weeks, 6 days, 2 hours, 55 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)